PCN170 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN ITALY
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.366
https://www.valueinhealthjournal.com/article/S1098-3015(19)32744-5/fulltext
Title :
PCN170 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN ITALY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32744-5&doi=10.1016/j.jval.2019.09.366
First page :
Section Title :
Open access? :
No
Section Order :
10303